Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
2014
Although core-binding factor-acute myeloid leukemia (CBF-AML) (t[8;21] or inv[16]/t[16;16]) represents a favorable cytogenetic AML subgroup, 30% to 40% of these patients relapse after standard intensive chemotherapy. The encouraging results of gemtuzumab ozogamicin (GO) in newly diagnosed AML, and
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
31
References
49
Citations
NaN
KQI